Impact of deucravacitinib on arthritis in patients with systemic lupus erythematosus: results from the phase II PAISLEY SLE study
8 affiliations
- 1Rheumatology, MedPharm Consulting Inc, Bethesda, Maryland, USA
- 2Department of Medicine, Division of Rheumatology, NYU Grossman School of Medicine, New York, New York, USA
- 3Rheumatology, Northwell Health, Great Neck, New York, USA
- 4Department of Medicine, The University of Queensland, Brisbane, Queensland, Australia
- 5Charité University Hospital Berlin, Berlin, Germany
- 6Bristol Myers Squibb, Princeton, New Jersey, USA
- 7Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA
- 8The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
Abstract
Objective: Assess the impact of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, on arthritis in patients with systemic lupus erythematosus (SLE) in a post-hoc analysis from the PAISLEY SLE study (NCT03252587).
Methods: PAISLEY SLE was a 48-week, global, double-blind, placebo-controlled, phase II study evaluating deucravacitinib (3 mg two times per day), 6 mg two times per day and 12 mg one time per day in SLE. Patients with ≥6 swollen, tender or active (swollen plus tender) joints and those with any joint involvement at baseline were evaluated from weeks 4 to 48. Arthritis efficacy was assessed by 100% reduction (JC-100) or ≥50% reduction (JC-50) from baseline in joint count using non-responder imputation. ORs were calculated using logistic regression. Proportions of patients demonstrating musculoskeletal involvement, as assessed by British Isles Lupus Assessment Group 2004 (BILAG-2004) and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) domain scores, were also evaluated.
Results: More patients achieved JC-100 with deucravacitinib versus placebo whether they had ≥1 or ≥6 tender or active joints at baseline. At week 48, JC-100 active joint responses in patients with ≥6 joints involved were deucravacitinib 3 mg two times per day (n=38/63), 60.3%; 6 mg two times per day (n=26/65), 40.0%; 12 mg one time per day (n=28/62), 45.2%; and placebo (n=20/64), 31.3%. At week 48, ORs for JC-100 for swollen, tender or active joints with deucravacitinib 3 mg two times per day versus placebo were 3.4, 2.0 and 3.3, respectively. Comparable responses and ORs were seen with achievement of JC-50 for swollen, tender or active joints at all deucravacitinib doses. More patients receiving deucravacitinib versus placebo had musculoskeletal score improvements by both BILAG-2004 and SLEDAI-2K at week 48.
Conclusion: Deucravacitinib was associated with improvements in arthritis in patients in the phase II PAISLEY SLE study. Results will be further evaluated in ongoing phase III studies.
Related
- Gaps in care for hydroxychloroquine retinopathy screening in patients with systemic lupus erythematosus or rheumatoid arthritis: a population-based cohort study.
- Serum IgG N-glycosylation profiles distinguish primary Sjögren’s disease, rheumatoid arthritis, and systemic lupus erythematosus and are associated with disease activity in Sjögren’s disease
- Comparison Between Systemic Lupus Erythematosus Patients with and Without Family History of Systemic Lupus Erythematosus—A Single-Center Retrospective Study
- Causes of hospitalization in systemic lupus erythematosus patients at a tertiary care center: insights from South Asia
- Machine-learning model for distinguishing cytomegalovirus infection status in hospitalised patients with systemic lupus erythematosus: a retrospective cohort study with temporal validation.
BibTeX
@article{pike2026impact,
title = {{Impact of deucravacitinib on arthritis in patients with systemic lupus erythematosus: results from the phase II PAISLEY SLE study}},
author = {Marilyn Pike and Amit Saxena and Richard A Furie and Peter Nash and Thomas Dörner and Coburn Hobar and Samantha Pomponi and Ying-Ming Jou and Subhashis Banerjee and Thomas Wegman and Joan T Merrill},
journal = {Lupus Science \& Medicine},
year = {2026},
month = oct,
doi = {10.1136/lupus-2026-002198},
url = {https://doi.org/10.1136/lupus-2026-002198},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Impact of deucravacitinib on arthritis in patients with systemic lupus erythematosus: results from the phase II PAISLEY SLE study
AU - Marilyn Pike
AU - Amit Saxena
AU - Richard A Furie
AU - Peter Nash
AU - Thomas Dörner
AU - Coburn Hobar
AU - Samantha Pomponi
AU - Ying-Ming Jou
AU - Subhashis Banerjee
AU - Thomas Wegman
AU - Joan T Merrill
PY - 2026
DA - 2026/10/29
JO - Lupus Science & Medicine
DO - 10.1136/lupus-2026-002198
UR - https://doi.org/10.1136/lupus-2026-002198
AB - Objective: Assess the impact of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, on arthritis in patients with systemic lupus erythematosus (SLE) in a post-hoc analysis from the PAISLEY SLE study (NCT03252587). Methods: PAISLEY SLE was a 48-week, global, double-blind, placebo-controlled, phase II study evaluating deucravacitinib (3 mg two times per day), 6 mg two times per day and 12 mg one time per day in SLE. Patients with ≥6 swollen, tender or active (swollen plus tender) joints and those with any joint involvement at baseline were evaluated from weeks 4 to 48. Arthritis efficacy was assessed by 100% reduction (JC-100) or ≥50% reduction (JC-50) from baseline in joint count using non-responder imputation. ORs were calculated using logistic regression. Proportions of patients demonstrating musculoskeletal involvement, as assessed by British Isles Lupus Assessment Group 2004 (BILAG-2004) and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) domain scores, were also evaluated. Results: More patients achieved JC-100 with deucravacitinib versus placebo whether they had ≥1 or ≥6 tender or active joints at baseline. At week 48, JC-100 active joint responses in patients with ≥6 joints involved were deucravacitinib 3 mg two times per day (n=38/63), 60.3%; 6 mg two times per day (n=26/65), 40.0%; 12 mg one time per day (n=28/62), 45.2%; and placebo (n=20/64), 31.3%. At week 48, ORs for JC-100 for swollen, tender or active joints with deucravacitinib 3 mg two times per day versus placebo were 3.4, 2.0 and 3.3, respectively. Comparable responses and ORs were seen with achievement of JC-50 for swollen, tender or active joints at all deucravacitinib doses. More patients receiving deucravacitinib versus placebo had musculoskeletal score improvements by both BILAG-2004 and SLEDAI-2K at week 48. Conclusion: Deucravacitinib was associated with improvements in arthritis in patients in the phase II PAISLEY SLE study. Results will be further evaluated in ongoing phase III studies.
SN - 2053-8790
ER -